NurExone is working on what sounds like science fiction—a therapy designed to regenerate
damaged nerve cells in the spinal cord, optic nerve, or other areas of the central nervous
system. If successful, this technology could potentially restore function in paralyzed patients—
or vision in those who lost it due to eye damage.
Despite this promise, many investors in Israel are not yet familiar with NurExone. One reason:
the company is in the pre-clinical stage, meaning human trials have not yet begun—typically
a phase where investors are more cautious. Another factor is its listing on the Canadian stock
exchange, a market less known to Israeli investors, and where it is rarer for Israeli companies
to list. This is combined with a relatively modest market cap of approximately CAD 52 million
(around USD 38 million), which keeps it below the radar of local institutional funds.